Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Gabapentin acid impurity 6 is a known impurity associated with Gabapentin acid. This compound is utilized primarily in the analysis of pharmaceutical formulations, ensuring the quality and safety of Gabapentin-based drugs. Its presence can be critical for researchers studying drug stability and efficacy in regulatory compliance settings. -
Drug Impurity
Nimesulide impurity 5 is an impurity associated with the non-steroidal anti-inflammatory drug, Nimesulide. This compound is of interest primarily for its potential influence on the pharmacokinetics and safety profile of the parent drug. It facilitates research on drug purity and quality control, aiding in the development of safe and effective pharmaceuticals. -
Drug Impurity
4-epi-Edoxaban is a known impurity of the anticoagulant Edoxaban. It plays a significant role in pharmacokinetic studies and quality control during the synthesis of Edoxaban, useful for assessing drug purity and stability. This compound is important for regulatory compliance and safety evaluations in drug development. Researchers can utilize 4-epi-Edoxaban to ensure the integrity of their Edoxaban formulations. -
Drug Impurity
Fluphenazine impurity 3 is a known impurity associated with the antipsychotic drug Fluphenazine. This compound serves as a critical reference standard in the analysis and quality control of Fluphenazine formulations. Its detection and quantification assist in ensuring the purity and safety of pharmaceutical products. This reagent is essential for researchers focusing on drug development, toxicology studies, and regulatory compliance within the pharmaceutical industry. -
Drug Impurity
Abiraterone impurity 15 is a chemical impurity of Abiraterone, a selective inhibitor of androgen biosynthesis. This compound is primarily utilized in quality control processes during pharmaceutical development to ensure the purity of Abiraterone formulations. Its presence in analytical studies aids in evaluating manufacturing methods and identifies potential degradation products that could impact drug efficacy and safety. -
Drug Impurity
Sitagliptin impurity 17 is a known impurity of the DPP-4 inhibitor Sitagliptin, which primarily targets the enzyme dipeptidyl peptidase-4. This compound serves as a valuable analytical reference standard for research involving the purity assessment and quality control of Sitagliptin formulations. It is essential for studies focused on pharmacokinetics, metabolism, and the overall safety profile of Sitagliptin. -
Drug Impurity
Dapagliflozin impurity 112 is a chemical impurity associated with the SGLT2 inhibitor Dapagliflozin. It serves as an important component for analytical and quality control studies in drug formulation. Researchers can utilize this impurity to evaluate the purity and stability of Dapagliflozin formulations, ensuring compliance with regulatory standards in pharmaceutical development. -
Drug Impurity
Rifaximin impurity 6 is a chemical compound associated with Rifaximin, primarily serving as a drug impurity. It is of significant interest in pharmaceutical research for its potential implications in drug formulation and quality control. As an impurity, it aids in the comprehensive assessment of Rifaximin's purity and efficacy, contributing to the development of safer therapeutic regimens. -
Drug Impurity
Trazodone impurity 14 is a chemical impurity associated with the antidepressant trazodone. It is relevant in pharmacological studies and quality control processes, useful for assessing the purity of trazodone formulations. Researchers can utilize this compound in investigations concerning drug synthesis, stability, and potential side effects, ensuring compliance with regulatory standards in pharmaceutical development. -
Drug Impurity
Ramipril impurity 1, also known as Ramipril methyl ester, is an impurity associated with the angiotensin-converting enzyme inhibitor Ramipril. Its characterization is critical in the quality control and validation of pharmaceutical products containing Ramipril. This compound serves as a reference standard in drug development and analytical chemistry for assessing the purity and stability of Ramipril formulations. -
Drug Impurity
Rosuvastatin impurity 9 is a known impurity of the cholesterol-lowering agent Rosuvastatin, primarily affecting its pharmacological profile. This compound is utilized primarily in the quality control and analysis of Rosuvastatin formulations to ensure compliance with regulatory standards. Its presence can offer insights into the synthesis and stability of the parent compound, making it important for pharmaceutical research and development. -
Drug Impurity
Clopidogrel impurity 9 is a known impurity associated with Clopidogrel, an antiplatelet medication. It serves as a reference standard for analytical and quality control studies, assisting in the characterization and evaluation of Clopidogrel formulations. This reagent is essential for ensuring the purity and compliance of pharmaceutical products during development and regulatory assessments. -
Drug Impurity
Indobufen impurity 16 is a known impurity of the anticoagulant compound Indobufen. This reagent is primarily used in pharmaceutical research and quality control to evaluate the purity and stability of Indobufen formulations. Its identification and characterization are critical for understanding the compound's safety and efficacy profiles in therapeutic applications. -
Drug Impurity
Duloxetine impurity 2 is a known impurity of the antidepressant Duloxetine, which primarily acts as a selective serotonin and norepinephrine reuptake inhibitor. This compound is utilized in pharmaceutical research to assess the purity of Duloxetine formulations and to understand the potential impact of impurities on drug efficacy and safety. Its characterization is essential for quality control and regulatory compliance in the development of Duloxetine-containing products. -
Drug Impurity
Fluticasone impurity 1 is a known impurity associated with Fluticasone, a corticosteroid utilized primarily for its anti-inflammatory properties. This compound plays a critical role in quality control and assurance during the synthesis and analysis of Fluticasone formulations. It is essential for researchers investigating drug purity and stability, as well as those developing analytical methods for the detection of impurities in pharmaceutical products. -
Drug Impurity
Clindamycin phosphate impurity 7, also known as Lincomycin 2-phosphate, serves as a drug impurity associated with Clindamycin phosphate. Its identification is crucial for the assessment of pharmaceutical formulations and quality control processes. This compound is primarily utilized in research concerning drug stability, impurities characterization, and regulatory compliance in the pharmaceutical industry. -
Drug Impurity
Tadalafil impurity 3, also known as Tadalafil impurity I, is a chemical impurity associated with Tadalafil. It is crucial for the quality control and characterization of Tadalafil in pharmaceutical formulations. Research applications include impurity profiling, stability testing, and compliance with regulatory standards in drug development. -
Drug Impurity
Fluphenazine decanoate impurity 6 is a known impurity of the antipsychotic agent fluphenazine decanoate. Its characterization is essential for the quality control of fluphenazine formulations, ensuring compliance with pharmaceutical standards. Researchers may utilize this compound in studies investigating the stability and degradation pathways of fluphenazine decanoate. -
Drug Impurity
Sofosbuvir Impurity 96 is a specified impurity associated with Sofosbuvir, an antiviral medication targeting the hepatitis C virus by inhibiting the NS5B polymerase. This compound serves as a critical reference standard in the analysis of Sofosbuvir formulations, ensuring quality control and compliance with pharmaceutical regulations. Its characterization is essential for laboratories conducting stability studies and impurity profiling in drug development processes. -
Drug Impurity
Montelukast impurity 4 is a chemical impurity associated with Montelukast, a leukotriene receptor antagonist used primarily in the treatment of asthma and allergic rhinitis. This impurity may be crucial for pharmaceutical quality control and regulatory compliance studies, investigating the safety and efficacy of Montelukast formulations. Its characterization aids in understanding potential impacts on therapeutic outcomes and ensures the reliability of drug products containing Montelukast. -
Drug Impurity
Rosuvastatin impurity 21 is a by-product of Rosuvastatin, a potent HMG-CoA reductase inhibitor. This impurity is important for analytical chemistry applications, particularly in the characterization and quality control of pharmaceutical formulations. Its identification and quantification can provide essential insights into the purity and safety of Rosuvastatin-containing products. -
Drug Impurity
Dabigatran impurity 1, also known as Dabigatran Carboxamide, is a known impurity of the anticoagulant Dabigatran. This compound serves as a reference standard in quality control and analytical testing, facilitating the assessment of Dabigatran's purity and stability. Its analysis is essential for ensuring the safety and efficacy of pharmaceutical formulations containing Dabigatran. -
Drug Impurity
Citalopram Impurity 3 Hydrobromide is a known impurity of the selective serotonin reuptake inhibitor Citalopram. This compound is utilized primarily in research settings to assess the purity and quality control of pharmaceutical formulations. Its presence can inform studies on drug stability and regulatory compliance in drug development processes. -
Drug Impurity
rel-trans-Ketoconazole is a drug impurity with relevance in pharmacological research. It serves as a crucial reference standard for the analytical characterization of ketoconazole formulations and related compounds. Its study aids in understanding the stability, safety, and efficacy profiles of ketoconazole derivatives in various biological systems. -
Drug Impurity
Salbutamol impurity 6 is a chemical compound associated with the drug impurity profile of salbutamol. It serves as a reference standard in the analysis and characterization of pharmaceutical formulations, aiding in the assessment of product quality and safety. This impurity can be utilized in research focused on drug metabolism and the development of analytical methods for detecting impurities in pharmaceutical products. -
Drug Impurity
Mesalazine impurity 8 is a known impurity of Mesalazine, a 5-aminosalicylic acid derivative used primarily in the treatment of inflammatory bowel diseases. This compound serves as an important analytical standard for assessing the purity of Mesalazine formulations. Its presence and quantification are essential for ensuring the quality and safety of pharmaceutical products containing Mesalazine. -
Drug Impurity
Benzaldehyde dimethyl acetal serves as a chemical reagent commonly identified as a drug impurity. This compound can impact the purity and safety profile of pharmaceutical formulations, making its analysis critical in drug development and quality control studies. It is utilized in researching stability, interactions, and the degradation pathways of various drug substances. -
Drug Impurity
Camptothecin impurity 1 is a structural variant associated with Camptothecin, an anticancer compound. This impurity may influence the pharmacological properties of Camptothecin and is relevant in the study of drug formulation and stability. Its characterization is crucial for quality control in research applications focused on cancer therapy and drug development. -
Drug Impurity
Paliperidone impurity 17 is a synthetic impurity associated with paliperidone, an atypical antipsychotic. It serves as a critical reference standard for quality control and method development in pharmaceutical research. This impurity is vital for the evaluation of drug purity and plays an essential role in ensuring the safety and efficacy of paliperidone formulations. -
Drug Impurity
Apremilast impurity 1 is a recognized impurity of the drug Apremilast, which targets phosphodiesterase 4 (PDE4). This compound is essential for quality control and analytical testing in pharmaceutical research, particularly in the development and validation of Apremilast formulations. Its characterization and quantification are crucial for ensuring the safety and efficacy of drug products. -
Drug Impurity
Rametimide impurity 16 is a structural impurity associated with Rametimide. This compound is critical for assessing the purity and quality of Rametimide formulations in pharmaceutical development. It serves as an important reference standard in drug analysis, stability testing, and regulatory compliance, aiding researchers in ensuring the integrity of their chemical formulations. -
Drug Impurity
Fluralaner impurity 2 is a drug impurity associated with the insecticide Fluralaner, which primarily targets the GABA and glutamate-gated chloride channels in arthropods. This compound serves as a valuable reference standard for analytical applications in quality control and method development related to Fluralaner synthesis and formulation. Its characterization aids in understanding the impurities' impact on pharmacological efficacy and safety profiles in research and regulatory contexts. -
Drug Impurity
Paliperidone impurity 3 is a known impurity of the antipsychotic agent Paliperidone, which primarily targets dopamine receptors. This compound is utilized in pharmaceutical research for quality control and to assess the purity of Paliperidone formulations. It serves as a crucial reference standard in the development and validation of analytical methods, ensuring compliance with regulatory standards in drug production. -
Drug Impurity
2-Methoxy-5-formylbenzoic acid is characterized as a drug impurity. It may arise during the synthesis of pharmaceutical compounds and is relevant for quality control in drug development. Its presence can affect the safety and efficacy profiles of drug products, making it crucial for researchers to monitor and analyze in various chemical analyses. -
Drug Impurity
Paracetamol Impurity 1 is a known impurity of the analgesic compound Paracetamol. This chemical is significant for quality control and regulatory compliance in pharmaceutical formulations containing Paracetamol. Its presence may affect drug efficacy and patient safety, making it essential for researchers to analyze and quantify during the development and testing of Paracetamol-based medications. -
Drug Impurity
Naproxen impurity 5 is a structural variant of Naproxen, primarily relevant in the context of drug formulation and stability studies. As a drug impurity, it serves as an important reference standard in analytical chemistry, allowing for the assessment of purity levels and potential effects on pharmacokinetics and toxicity profiles. Researchers can utilize this reagent for quality control, ensuring the safety and efficacy of Naproxen-containing pharmaceuticals. -
Drug Impurity
Rivaroxaban impurity 50, also known as thiophene-2-carboxylate, is a known impurity associated with Rivaroxaban. This compound is pertinent for quality control and analytical research in pharmaceutical development, particularly in evaluating the purity of Rivaroxaban. Its presence and quantification are critical for ensuring the safety and efficacy of finished drug products. -
Drug Impurity
Ledipasvir impurity 53 is a known impurity of the antiviral compound Ledipasvir, which acts primarily as an NS5A inhibitor. This chemical research reagent is relevant for studies focusing on the characterization and analysis of drug purity in pharmaceutical development and quality control. Its presence and quantification can provide insights into the synthesis and stability of ledipasvir-containing formulations, facilitating improved quality assurance practices. -
Drug Impurity
3-Ethoxy-4-hydroxybenzonitrile is identified as a drug impurity with potential significance in pharmaceutical development. This compound may influence the stability, efficacy, and safety profiles of drug formulations. Its presence should be monitored in analytical assays to ensure quality control and regulatory compliance in chemical research and drug manufacturing applications. -
Drug Impurity
Mesalazine impurity 2 is a known impurity associated with the anti-inflammatory drug Mesalazine. This compound is utilized primarily in analytical chemistry for quality control and characterization of Mesalazine formulations. Its presence can impact the efficacy and safety of pharmaceutical products, making it important for drug development and regulatory compliance studies. -
Drug Impurity
Cholic acid impurity 1 is a chemical impurity associated with cholic acid, a primary bile acid involved in the digestion and absorption of fats. This compound is crucial for quality control and characterization in pharmaceutical research, particularly in the context of drug formulation and assessment of purity. Cholic acid impurity 1 supports investigations into the safety and efficacy of compounds that include cholic acid within their formulations. -
Drug Impurity
Methyl phenyl sulfone is a sulfone compound often identified as a drug impurity in pharmaceutical formulations. It can affect drug stability and bioavailability, making it significant in analytical chemistry and quality control. Researchers utilize this reagent to assess purity in drug synthesis and to evaluate the potential impact of impurities on pharmacological profiles. -
Drug Impurity
Tofacitinib impurity 3 is a known impurity of the JAK1/3 inhibitor Tofacitinib. It is primarily utilized for assessing the purity and quality of Tofacitinib in pharmaceutical formulations. This impurity serves as a valuable reference standard in the development and analysis of therapeutic agents targeting immune-mediated disorders. -
Drug Impurity
Metformin impurity 1 is a known impurity associated with the antidiabetic agent Metformin. This compound is important for quality control and regulatory compliance in pharmaceutical research, particularly in the analysis of drug formulations. Its presence and characterization are critical for ensuring the purity and efficacy of Metformin-containing products. -
Drug Impurity
Nintedanib impurity 4 is a known impurity of the multi-kinase inhibitor, Nintedanib, which primarily targets VEGFR, FGFR, and PDGFR pathways. This compound serves as a reference standard for the evaluation of drug purity and stability in pharmaceutical development. It is essential for researchers investigating the pharmacokinetics, safety, and regulatory compliance of Nintedanib in various biological assays and analytical methods. -
Drug Impurity
Apixaban impurity 41 is a known impurity associated with Apixaban, a direct factor Xa inhibitor. This compound is utilized in the pharmaceutical research setting to assess the purity and quality of Apixaban formulations. Its characterization is crucial for regulatory compliance and ensuring the therapeutic efficacy of Apixaban in clinical applications. -
Drug Impurity
Olanzapine impurity 2 hydrochloride is a known impurity of the antipsychotic compound, Olanzapine hydrochloride. This reagent plays a critical role in drug quality control and formulation research, facilitating the assessment of purity and stability in pharmaceutical preparations. Its examination is essential for regulatory compliance and the development of safer therapeutic agents. -
Drug Impurity
Methyl 2-tert-Butyloxycarbonylaminoacrylate is characterized as a drug impurity that may emerge during the synthesis of pharmaceutical compounds. This compound serves as a key reference standard in analytical chemistry, aiding in the identification and quantification of related substances in drug development. Its presence is relevant for ensuring the purity and safety profiles of therapeutic agents. -
Drug Impurity
Apixaban impurity 13 is a chemical impurity associated with the anticoagulant drug Apixaban. This compound is critical for analytical and quality control studies in pharmaceutical research, particularly in assessing the purity of Apixaban formulations. The presence of such impurities can affect the pharmacological profile and safety of the final product, making it essential for ensuring compliance with regulatory standards in drug development. -
Drug Impurity
N,N-Dibenzylacetamide is a drug impurity commonly encountered in pharmaceutical formulations. Its presence can influence the pharmacokinetics and efficacy of active pharmaceutical ingredients. This compound is of particular interest for analytical research focused on drug quality assessment and regulatory compliance. Understanding and analyzing impurities such as N,N-Dibenzylacetamide is crucial for ensuring the safety and effectiveness of drug products.
